missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Elotuzumab Recombinant Monoclonal Antibody
Recombinant Monoclonal Antibody
Brand: Invitrogen™ MA558401
This item is not returnable.
View return policy
Description
For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °.
Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. Elotuzumab consists of the complementary determining regions (CDR) of the mouse antibody, MuLuc63, grafted onto human IgG1 heavy and kappa light chain frameworks. Elotuzumab is produced in NS0 cells by recombinant DNA technology. Elotuzumab has a theoretical mass of 148. 1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U. S. Food and pharmaceutical Administration. Elotuzumab is marketed under the brand Empliciti™ by Bristol-Myers Squibb.
Specifications
| Elotuzumab Humanized | |
| Recombinant Monoclonal | |
| Unconjugated | |
| BMS-901608; PDL063;HuLuc63 | |
| Protein A | |
| RUO | |
| Human | |
| Antibody | |
| IgG1 κ |
| ELISA, Flow Cytometry, Functional Assay, Surface Plasmon Resonance | |
| 1 mg/mL | |
| 25mM histidine with 0.01% Tween 80, 8% sucrose and no preservative; pH 6.2 | |
| Human | |
| 100 μg | |
| Primary | |
| -20°C, Avoid Freeze/Thaw Cycles | |
| Lyophilized |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction